Oncology Update

News for physicians from Legacy Cancer Institute Summer 2013

Inside this issue

New options for brain tumors. . . . 3

Legacy upgrades radiation at three sites 3

Collaboration brings improved care to more people

To improve access to advanced cancer care, Legacy Health and Oregon Health & Science University (OHSU) recently signed a joint operating agreement for eight community outpatient cancer clinics serving Multnomah, Washington, Clackamas, Columbia and Clark counties. The clinical integration afforded by the newly created OHSU Knight–Legacy Health Cancer Collaborative enhances both organizations' ability to deliver the best available cancer care — including radiation oncology, medical oncology and infusion services — in communities where patients live. (See page 2 for a complete list of sites.)

"By leveraging each organization's respective expertise and resources, the OHSU Knight–Legacy Health Cancer Collaborative will deliver the most advanced and personalized care to our patients," said George J. Brown, M.D., president and chief executive officer of Legacy Health.

Peter Rapp, OHSU executive vice president and executive director of OHSU Healthcare, said, "By complementing each other's strengths, we will be able to achieve much more together on behalf of patients than would be possible on our own."

"OHSU and Legacy share a sense of urgency in improving not only treatment options, but the quality of life of our cancer patients," said Brian Druker, M.D., director of the OHSU Knight Cancer Institute.

"The driving force behind this collaboration is to deliver the best possible cancer care in the most seamless and efficient way possible," said Nathalie Johnson, M.D., medical director of Legacy Cancer Institute. "From access to the best available clinical trials and research to a greater number of treatment locations so patients can stay closer to home, we look forward to putting into action the many smart solutions inherent in [this agreement]."

"The driving force behind this collaboration is to deliver the best possible cancer care."

— Nathalie Johnson, M.D., medical director Legacy Cancer Institute

To refer, please see the list on page 2. For more information, call 503-413-8050.

What the collaboration means for patients

- Treatment provided in multiple locations, so patients can stay closer to home
- Coordinated, multidisciplinary cancer therapy from OHSU and Legacy physicians working together
- Access to cutting-edge clinical trials offered through the cancer institutes' combined community practices

LEGACY HEALTH

OHSU KNIGHT – LEGACY HEALTH CANCER COLLABORATIVE

Locations and physicians

Legacy Comprehensive Cancer Center–Good Samaritan

Radiation oncology — 503-413-7135
Andrew Kee, M.D.
Misa Lee, M.D.
Won Lee, M.D.
Kathryn Panwala, M.D.
Mark Schray, M.D.

Infusion (including chemotherapy) — 503-413-7781

OHSU Knight Community Hematology Oncology Northwest

Medical oncology — 503-299-6500
Eric Anderson, M.D., Ph.D.
Robert Raish, M.D.
Jacqueline Vuky, M.D.

Legacy Emanuel Medical Center

Infusion (including chemotherapy) — 503-413-4608

Legacy Meridian Park Medical Center

Infusion (including chemotherapy) — 503-692-2521

OHSU Knight Community Hematology Oncology Tualatin

Medical oncology — 503-885-9789
Fred Ey, M.D., FACP
Kevin Yee, M.D.

Legacy Mount Hood Medical Center

Radiation oncology — 503-674-1152
Andrew Kee, M.D.
Misa Lee, M.D.
Won Lee, M.D.
Kathryn Panwala, M.D.
Mark Schray, M.D.

Infusion (including chemotherapy) — 503-674-1249

OHSU Knight Community Hematology Oncology Gresham

Medical oncology — 503-661-1112
Drew Chen, D.O.
Samir Desai, M.D.
Kathryn Shell, M.D.

Legacy Salmon Creek Medical Center

Radiation oncology — 360-487-1700
Andrew Kee, M.D.
Misa Lee, M.D.
Won Lee, M.D.
Kathryn Panwala, M.D.
Mark Schray, M.D

Infusion (including chemotherapy) — 360-487-1750

OHSU Knight Community Hematology Oncology Beaverton

Medical oncology and infusion services — 503-203-1000
Katherine Barford, M.D.
Fred Ey, M.D., FACP
Gary Takahashi, M.D., FACP
Kevin Yee, M.D.

Radiation oncology — 503-601-6400
Carol Marquez, M.D.

OHSU Knight Radiation Medicine

503-494-8756
John Holland, M.D.
Arthur Hung, M.D.
Charlotte Kubicky, M.D., Ph.D.
Carol Marquez, M.D.
Charles Thomas, Jr., M.D.

Go paperless To receive this newsletter electronically, send your email address to istupfel@lhs.org.

New technology offers options for brain tumor patients

New technology at Legacy Cancer Institute is transforming brain tumor treatment, offering hope to patients with previously inoperable lesions. Legacy Health is the only system on the West Coast to offer both NICO BrainPath® minimally invasive brain surgery and ultra-precise Gamma Knife stereotactic radiosurgery. Each works alone — and together — to target complex and/or deep-seated lesions and minimize damage to nearby healthy tissue, eliminating or reducing post-procedural functional deficits.

BrainPath incorporates advanced imaging, mapping and high-definition intraoperative optics, enabling the neurosurgeon to pinpoint the tumor and guide access to it. BrainPath's narrow probe minimizes damage through brain tissue. The tumor is removed with a pencil-thin tool that generates no heat, helping to preserve adjacent critical structures.

"BrainPath allows us to use a less-invasive approach to get to deep-seated lesions while sparing normal white-matter tracts," says Jefferson Chen, M.D., Ph.D., the first neurosurgeon on the West Coast to use the system, performing 10 procedures to date. He performs this technique at Legacy Emanuel Medical Center, one of only 12 U.S. hospitals to offer it.

The technology is particularly efficacious with tumors previously considered inoperable or with a poor prognosis, including gliomas and multiple brain metastases. It also enables treatment of hemorrhagic stroke while preserving brain function — an intervention once thought impossible.

The Gamma Knife is a form of stereotactic radiosurgery considered the gold standard in nonsurgical treatment of brain metastases and inoperable brain lesions. Treatment is completed in a day; recovery takes a few days. Because it is precise and targeted, it minimizes radiation exposure, enabling retreatment.

Radiation oncologist Andy Kee, M.D., and Dr. Chen are physician leaders of the Legacy Gamma Knife Center at Legacy Good Samaritan Medical Center. Neurosurgeons Frank Soldevilla, M.D., David Adler, M.D., and Richard Polin, M.D., also are credentialed on the Gamma Knife.

In addition to these advanced treatment options for brain lesions, Legacy addresses patients' complete needs with a social worker, stress management therapist, registered dietitian, massage therapist and a certified nurse practitioner with expertise in integrative therapies and symptom management.

To learn more: **www.legacyhealth.org/braintumor**. Or contact Dr. Chen at 503-528-0704 (jchen@lhs.org) or Dr. Kee at 503-413-6172 (akee@lhs.org).

Radiation oncology upgrades advance Legacy's cancer care

Legacy Good Samaritan, Legacy Mount Hood and Legacy Salmon Creek medical centers have upgraded their radiation oncology technology with the launch of three Elekta Infinity™ linear accelerators to deliver the most precise and effective radiation therapy available today.

"Legacy Cancer Institute is thrilled to bring this caliber of cancer care to patients in East County," said Kathryn Panwala, M.D., Legacy Cancer Institute radiation oncologist at Legacy Mount Hood.

The upgrade gives Legacy Mount Hood and Salmon Creek medical centers the ability to treat patients with stereotactic body radiation therapy (SBRT), an extremely targeted and intensified form of radiation therapy particularly effective in early-stage lung cancers, spinal cord tumors and hepatocellular carcinoma. SBRT also allows for re-treatment of patients previously ineligible for repeat radiation. Legacy Good Samaritan has been refining the technology for years.

For more: **www.legacyhealth.org/radiation**.

Legacy Health
Legacy Cancer Institute
1919 N.W. Lovejoy St.
Portland, OR 97209

Nonprofit Org.
U.S. Postage
PAID
Permit No. 11
Portland, OR

Inside —

Collaboration seeks to improve care

New options for brain tumors

Legacy radiation oncology centers see upgrades

Oncology Update

Clinical trials available for patients

Oncology research at Legacy Health has many clinical trials available for patients with a cancer diagnosis.

Newly opened

- SWOG S1117 — Randomized Phase II study of azacitidine in combination with lenalidomide vs. azacitidine alone vs. azacitidine in combination with vorinostat for higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Lenalidomide and vorinostat provided by the study.

Opening soon

- Alliance A221101 — Phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil®) to reduce cancer-related fatigue in patients with glioblastoma multiforme. Armodafinil or placebo provided by the study.
- SWOG S1207 — Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/– one year of everolimus in patients with high-risk, hormone receptor-positive and her2/neu negative breast cancer. Everolimus or placebo provided by a pharmaceutical collaborator.
- SWOG S1216 — Phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer. TAK-700 provided by a pharmaceutical collaborator.
- NSABP B51 — Phase III randomized clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy.

CAN-4338 ©2013